Literature DB >> 12852883

The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas.

Jan Cap1, Jaroslav Cerman, Stanislav Nemecek, Martina Marekova, Vaclav Hana, Zdenek Frysak.   

Abstract

With the aim to investigate histopathological changes and proliferative and apoptotic activity in GH-secreting adenomas we compared 14 cases pre-treated with somatostatin analogues before surgery with a reference group of 17 un-pretreated ones. Besides routine histology, immunocytochemical detection of all pituitary hormones, caspase-3, cytokeratin-18, and "M30 antigen", its apoptosis-specific fragment was performed. Proliferation activity of the tumour was determined by the Ki-67 antigen expression. In treated adenomas more prominent regressive changes were found accompanied by compensatory increase in perivascular fibrosis. The Ki-67 labelling index was lower in treated group (mean 2.5, median 1.6 per mille) than in untreated patients (mean 9.4, median 5.0 per mille). The difference was statistically significant (p=0.049 using Mann-Whitney Rank Sum Test). Apoptosis was detected in only 2 of the 14 pre-treated adenomas, and it was more frequent (9/17) and more prominent in the untreated group.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12852883     DOI: 10.1016/s0967-5868(03)00072-9

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  6 in total

1.  Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas.

Authors:  Mark Gruppetta; Robert Formosa; Sharon Falzon; Sabrina Ariff Scicluna; Edward Falzon; James Degeatano; Josanne Vassallo
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

Review 2.  Pituitary somatostatin receptor signaling.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Trends Endocrinol Metab       Date:  2010-02-09       Impact factor: 12.015

3.  Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas.

Authors:  Filip Gabalec; Martin Beranek; David Netuka; Vaclav Masopust; Jiri Nahlovsky; Tomas Cesak; Josef Marek; Jan Cap
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 4.  Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.

Authors:  Richard A Feelders; Leo J Hofland; Maarten O van Aken; Sebastian J Neggers; Steven W J Lamberts; Wouter W de Herder; Aart-Jan van der Lely
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

Review 5.  Antiproliferative effects of somatostatin analogs in pituitary adenomas.

Authors:  Maria Chiara Zatelli; Daniela Piccin; Maria Rosaria Ambrosio; Marta Bondanelli; Ettore C degli Uberti
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

Review 6.  Preoperative Medical Treatment for Patients With Acromegaly: Yes or No?

Authors:  Frederique Albarel; Thomas Cuny; Thomas Graillon; Henry Dufour; Thierry Brue; Frederic Castinetti
Journal:  J Endocr Soc       Date:  2022-08-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.